Caisse DE Depot ET Placement DU Quebec Buys New Shares in Catalent, Inc. (NYSE:CTLT)

Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Catalent, Inc. (NYSE:CTLT) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 645,243 shares of the company’s stock, valued at approximately $39,082,000.

Several other large investors have also recently added to or reduced their stakes in the company. Brooklyn Investment Group bought a new position in Catalent in the third quarter worth $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent in the 2nd quarter valued at $42,000. Sentry Investment Management LLC acquired a new stake in shares of Catalent during the 3rd quarter valued at about $53,000. Longfellow Investment Management Co. LLC boosted its position in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares during the period.

Insider Transactions at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CTLT shares. StockNews.com lowered Catalent from a “hold” rating to a “sell” rating in a research note on Friday, November 22nd. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reiterated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Finally, Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to data from MarketBeat.com, Catalent has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Price Performance

Catalent stock opened at $61.11 on Monday. The business’s fifty day moving average is $59.90 and its two-hundred day moving average is $58.51. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The firm has a market cap of $11.09 billion, a P/E ratio of -27.04, a P/E/G ratio of 2.43 and a beta of 1.16. Catalent, Inc. has a 52 week low of $36.74 and a 52 week high of $61.50.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the firm earned ($0.10) earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. Equities research analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.